Disc Medicine, Inc.

IRON

NASDAQ

Healthcare

Biotechnology

Watertown, MA, US94 employeesdiscmedicine.com

$65.22

+0.44(0.68%)

Mkt Cap $2.5B

$34.28

$94.11

52-Week Range

At a Glance

AI-generated

8-K

Disc Medicine, Inc. approved a restructuring plan on February 26, 2026, reducing its workforce by approximately 20% primarily in commercial and supporting functions, following an FDA complete response letter on February 13, 2026, for its bitopertin NDA. The Company expects $2.0 million in aggregate charges, mainly severance, in Q1 2026.

$2.5B

Market Cap

—

Revenue

-$229M

Net Income

Employees94

Fundamentals

How The Business Makes Money

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Industry Biotechnology

Activity

What Changed Recently

Impairment

Feb 26, 2026

Costs Associated with Exit or Disposal Activities. On February 26, 2026, the board of directors of Disc Medicine, Inc. (the “Company”) approved, and management

Financial Results

Feb 25, 2026

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section

Financial Results

Jan 11, 2026

of this Current Report on Form 8-K is intended to be furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchan

Regulation FD

Feb 16, 2026

of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securi

Regulation FD

Feb 12, 2026

of this Current Report on Form 8‑K and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Ex

Peer Companies

Company	Price	Change	Market Cap	P/E
SRRKScholar Rock Holding Corp...	$50.27	+1.87%	$5.8B	-13.3
CGONCG Oncology, Inc. Common ...	$67.48	+1.03%	$5.7B	-31.2
CELCCelcuity Inc.	$112.58	-0.31%	$5.4B	-29.4
APGEApogee Therapeutics, Inc.	$84.23	-0.01%	$4.7B	-18.8
XENEXenon Pharmaceuticals Inc...	$56.70	+0.02%	$4.5B	-12.5
LEGNLegend Biotech Corporatio...	$19.10	+0.26%	$3.5B	-10.7
TARSTarsus Pharmaceuticals, I...	$69.90	-0.46%	$3.0B	-41.3
AAPGASCENTAGE PHARMA GROUP IN...	$26.61	+1.26%	$2.5B	-11.3

Analyst View

Company Profile

CIK0001816736

ISINUS2546041011

Phone617 674 9274

Address321 Arsenal Street, Watertown, MA, 02472, US

SEC EDGAR